考比替尼和维莫非尼诱发的肉芽肿性皮炎和硬红斑：一例报告。
Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report.
作者信息
Iafolla Marco Aj, Ramsay Jennifer, Wismer Judy, McWhirter Elaine
机构信息
Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Department of Pathology and Molecular Medicine, Juravinski Hospital, McMaster University, Hamilton, ON, Canada.
出版信息
SAGE Open Med Case Rep. 2019 May 16;7:2050313X19847358. doi: 10.1177/2050313X19847358. eCollection 2019.
Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition. Here, we describe the first reported case of a patient with metastatic melanoma who developed granulomatous dermatitis and erythema induratum when treated with combination BRAF (vemurafenib) and MEK inhibitor (cobimetinib) therapy and discuss the clinical features and management of dermatologic side-effects secondary to BRAF +/- MEK inhibition.
转移性黑色素瘤是一种侵袭性恶性肿瘤。联合使用BRAF和MEK抑制剂可提高生存率。BRAF抑制剂引起的皮肤毒性可通过MEK抑制得到减轻。在此，我们报告首例接受BRAF（维莫非尼）和MEK抑制剂（考比替尼）联合治疗的转移性黑色素瘤患者发生肉芽肿性皮炎和硬结性红斑的病例，并讨论BRAF ± MEK抑制继发的皮肤副作用的临床特征及处理。
Zotero 插件